This study presents a novel optoporation technique using a titanium-coated TiO microstructure (TMS) device activated by an infrared diode laser for highly efficient intracellular delivery. The TMS device, fabricated with 120 nm titanium coating on a titanium dioxide (TiO) microstructure containing microneedles (height ∼2 μm and width ∼4.5 μm), demonstrates enhanced biocompatibility and thermal conductivity compared to the conventional TiO microstructure (MS). Exposure to the TMS device with an IR diode laser (980 nm) generates heat, forming photothermal bubbles that disrupt the cell membrane and create transient pores for biomolecular delivery. Unlike traditional optoporation methods, which rely on large, vibration-sensitive lasers, the IR diode laser-assisted TMS device-based optoporation technique offers a compact, cost-effective, and portable alternative, making it suitable for clinical and research applications in resource-constrained environments. The performance of the TMS and MS devices was compared in various cancer cell lines (HeLa, L929, and N2a), with the TMS device showing superior delivery success rates for biomolecules of varying molecular sizes. Notably, the TMS device achieved a 99.30% delivery success rate for the smallest molecule, PI dye, and an 85.17% success rate for the largest studied molecule, β-galactosidase enzyme-Cy5. Furthermore, the TMS device consistently provided a higher delivery success rate at lower laser power, minimizing cellular stress and preserving cell survivability. Moreover, using Western Blot analysis, the TMS device demonstrated lower levels of apoptosis compared to the MS device, with statistically significant differences, highlighting its potential for efficient intracellular delivery while minimizing cellular stress and damage. These results highlight the potential of the TMS device as an advanced tool for large-size intracellular biomolecular delivery, offering significant improvements in stability, efficiency, and cell survivability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.4c17618 | DOI Listing |
Am J Psychiatry
January 2025
Centre Hospitalier de l'Université de Montréal (CHUM) and Centre de Recherche du CHUM (CRCHUM), University of Montreal, Montreal (Couture, Desbeaumes Jodoin, Bousseau, Sarshoghi, Miron, Lespérance); IfADo Leibniz Research Center for Working Environment and Human Factors at TU Dortmund, Germany, and Bielefeld University, University Hospital OWL, Protestant Hospital of Bethel Foundation, University Clinic of Psychiatry and Psychotherapy, and German Center for Mental Health (Nitsche); Temerty Centre for Therapeutic Brain Intervention and Campbell Family Research Institute, Centre for Addiction and Mental Health (CAMH) and Department of Psychiatry, University of Toronto, Toronto (Blumberger); Department of Medicine (Bolduc) and Department of Psychiatry and Addictology (Lespérance, Miron), Faculty of Medicine, University of Montreal, Montreal; Interventional Psychiatry Program, Department of Psychiatry, UC San Diego School of Medicine, San Diego (Weissman, Appelbaum, Daskalakis, Poorganji, Miron).
Objective: This study investigated spaced transcranial direct current stimulation for major depressive disorder, focusing on feasibility.
Methods: In a prospective open-label study, 30 participants with major depressive disorder were enrolled to receive a 50-session transcranial direct current stimulation (tDCS) treatment over 2 weeks. The feasibility, safety, tolerability, and preliminary therapeutic effects of this tDCS protocol were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline and 1-week and 4-week follow-ups, as well as with the 6-item HAM-D (HAM-D-6) daily during treatment.
Neuroimage
January 2025
Center for Mind/Brain Sciences (CIMeC), University of Trento, 38068 Rovereto (TN), Italy.
Transcranial magnetic stimulation (TMS) has the potential to yield insights into cortical functions and improve the treatment of neurological and psychiatric conditions. However, its reliability is hindered by a low reproducibility of results. Among other factors, such low reproducibility is due to structural and functional variability between individual brains.
View Article and Find Full Text PDFJ Neural Eng
January 2025
Huazhong University of Science and Technology Wuhan National High Magnetic Field Center, No.1037, Luoyu Road, Wuhan, Hubei, 430074, CHINA.
Objective: Pulse parameter controllable transcranial magnetic stimulation (cTMS) devices with fully-controlled semiconductor switches are increasingly being developed, but the primary waveform they generate is often accompanied by ringing, which is due to the resonance between the stimulation coil inductance and the snubber capacitors paired with the switches at the end of the pulse. This study provides a ringing suppression design method to effectively suppress it and reduce its impact on stimulation efficacy.
Methods: A three-pronged design method is developed to suppress the ringing at its source.
ACS Appl Mater Interfaces
January 2025
Department of Engineering Design, Indian Institute of Technology Madras, Chennai 600036, India.
This study presents a novel optoporation technique using a titanium-coated TiO microstructure (TMS) device activated by an infrared diode laser for highly efficient intracellular delivery. The TMS device, fabricated with 120 nm titanium coating on a titanium dioxide (TiO) microstructure containing microneedles (height ∼2 μm and width ∼4.5 μm), demonstrates enhanced biocompatibility and thermal conductivity compared to the conventional TiO microstructure (MS).
View Article and Find Full Text PDFJAMA Neurol
January 2025
Department of Neural and Pain Sciences, University of Maryland School of Dentistry, Baltimore.
Importance: Biomarkers would greatly assist decision-making in the diagnosis, prevention, and treatment of chronic pain.
Objective: To undertake analytical validation of a sensorimotor cortical biomarker signature for pain consisting of 2 measures: sensorimotor peak alpha frequency (PAF) and corticomotor excitability (CME).
Design, Setting, And Participants: This cohort study at a single center (Neuroscience Research Australia) recruited participants from November 2020 to October 2022 through notices placed online and at universities across Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!